SPARC与CXCL1在前列腺癌中的表达及意义

Expression and Significance of SPARC and CXCL1 in Prostate Cancer

目的研究富含半胱氨酸的酸性蛋白(SPARC)与趋化因子1(CXCL1)在前列腺癌中的表达及其与前列腺癌的关系。方法采用免疫组织化学(SP法)检测38例前列腺癌组织(观察组)和20例良性前列腺增生组织(对照组)中SPARC与CXCL1的表达,分析其与前列腺癌分期、分级的关系。结果观察组和对照组SPARC的阳性表达率分别为92.1%和70.0%,2组比较差异无统计学意义(P>0.05)。观察组Gleasion评分低分化和术后淋巴结阳性者SPARC的表达显著增强(P<0.05)。观察组CXCL1的阳性表达率高于对照组(89.5%比10.0%,P<0.05);在恶性程度高的前列腺癌标本中,CXCL1的表达强度增强(P<0.05)。结论 SPARC在前列腺癌和前列腺增生组织中呈无差异表达,但在侵袭性前列腺癌中表达明显增强,且与前列腺癌的分级和分期关系密切,并对前列腺癌的预后判断有参考价值。CXCL1在前列腺癌中的表达阳性率增强,阳性表达强度与前列腺癌的分级分期关系密切,对前列腺癌的诊断和预后有参考价值。

Objective To investigate the expression and significance of secreted protein acidic and rich in cysteine(SPARC)and chemokine ligand 1(CXCL1)in prostate cancer.Methods The expression of SPARC与 CXCL1 was detected by immunohistochemistry in 38 prostate cancer tissues(observation group)and 20 benign prostate hyperplasia samples(control group).The relationships of SPARC and CXCL1 expression to prostate cancer staging and grading were analyzed.Results There was no significant difference in positive rate of SPARC expression between observation group(92.1%)and control group(70.0%)(P>0.05).However,the expression of SPARC remarkablely increased in patients with low Gleason score and lymph node positive prostate cancer(P<0.05).In addition,the expression of CXCL1 obviously increased in highly malignant prostate cancer(P<0.05).Conclusion There is no difference in SPARC expression between prostate cancer and prostatic hyperplasia tissues.However,SPARC expression increases in invasive prostate cancer and is correlated with prostate cancer staging and grading,suggesting that SPARC is valuable for predicting prognosis of prostate cancer.The expression of CXCL1 increases in prostate cancer and is closely related to prostate cancer staging and grading,demonstrating that CXCL1 has a reference value for the diagnosis and prognosis of prostate cancer.